Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Imidazoline receptors are a family of nonadrenergic binding sites classified into three main subtypes: I1, I2, and I3. They play diverse roles in various physiological processes, including blood pressure regulation, insulin secretion, pain modulation, and neuroprotection. The precise molecular identities of these receptors remain elusive, and ongoing research aims to fully characterize their structure and function, as well as develop more selective and effective therapeutic agents.
I1 agonists lower blood pressure by reducing central sympathetic outflow. I2 ligands allosterically modulate monoamine oxidase B (MAO-B). I3 ligands regulate insulin secretion, possibly via ATP-sensitive K+ channels.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Imidazoline Receptor (IR).